SEC filing summary
Issuer identity: The filing is for Trxade Group, Inc., not Scienture Holdings, Inc. The filing covers the quarter ended June 30, 2015; financial statements are unaudited.
Business context and reporting period
Trxade operated a web-based pharmaceutical marketplace connecting independent pharmacies with suppliers. Its subsidiaries also sold pharmaceuticals and provided IT consulting. This Form 10-Q reports the three and six months ended June 30, 2015, compared with the corresponding 2014 periods.
Financial performance and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $1.167 million | $288 thousand | $1.863 million | $532 thousand |
| Gross profit | $785 thousand | $237 thousand | $1.251 million | $334 thousand |
| Gross margin | 67.3% | 82.2% | 67.1% | 62.8% |
| Operating loss | $26 thousand | $300 thousand | $469 thousand | $645 thousand |
| Net loss | $54 thousand | $301 thousand | $498 thousand | $1.223 million |
At June 30, 2015, cash was $414 thousand; current assets were $1.527 million and current liabilities $1.081 million, yielding working capital of $446 thousand. Total assets were $1.528 million, total liabilities approximately $1.081 million, and shareholders’ equity $447 thousand. Cash fell $291 thousand from year-end 2014.
For the first half, operating cash outflow was $696 thousand, versus $412 thousand in 2014; financing provided $405 thousand, mainly from borrowings. The company reported $200 thousand face value of one-year convertible notes bearing 10% interest, convertible at $1.50 per share, and a $250 thousand face-value promissory note issued for $205 thousand net proceeds. At period-end, these appeared as current liabilities net of unamortized discounts: $111 thousand and $213 thousand, respectively. No cash dividends were reported.
Changes, outlook, and risks
- First-half revenue increased substantially, which management attributed mainly to platform fee income and added customers; pharmaceutical sales also increased cost of sales.
- First-half net loss narrowed, partly because 2014 included a $576 thousand loss on debt conversion. General and administrative costs increased with staffing and operational expansion; management cited $831 thousand of payroll expense for the first half.
- Management estimated approximately $4.7 million of operating expenses and working-capital requirements for the next 12 months, including $1.2 million of cost of sales and $3.5 million of general and administrative expenses. It stated that additional funding would be needed and that financing availability and terms were uncertain. No formal revenue or earnings guidance was provided.
- Potential dilution includes 50,000 warrants issued with the convertible notes and employee options. The filing reports 31,269,160 common shares outstanding at July 30, 2015.
- Management concluded disclosure controls and procedures were not effective. It reported no material change in internal control over financial reporting during the first half. The filing marked “No” to whether all required Exchange Act reports had been filed during the preceding 12 months.
- The filing reported no legal proceedings and no defaults upon senior securities. It cautioned that results may differ from forward-looking statements and referred investors to the risk factors in the annual report.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing names Trxade Group, Inc., while the request metadata names Scienture Holdings, Inc.
- Assess whether available cash, working capital, and prospective financing can cover the stated next-12-month requirements and continuing operating cash burn.
- Review the convertible-note terms, discounts, warrants, and possible dilution, along with the outstanding employee options.
- Investigate the stated ineffective disclosure controls and the “No” response concerning timely filing history.
- Reconcile expense presentation: the financial statements present general and administrative expense totals that include amounts separately described as warrant and option expense in management’s discussion.